APA
Click to copy
Cruz-González, A., Aguilar-Cámara, A., Alvarez-Carreño, C., Becerra, A., Campillo-Balderas, J. A., Cisneros-Martínez, A., … Lazcano, A. (2020). SARS-CoV-2 Exoribonuclease (NSP14) As a Potential Therapeutic Target to Treat COVID-19.
Chicago/Turabian
Click to copy
Cruz-González, A., Abelardo Aguilar-Cámara, Claudia Alvarez-Carreño, A. Becerra, J. A. Campillo-Balderas, A. Cisneros-Martínez, Grisel Córdova-Villalba, et al. “SARS-CoV-2 Exoribonuclease (NSP14) As a Potential Therapeutic Target to Treat COVID-19” (2020).
MLA
Click to copy
Cruz-González, A., et al. SARS-CoV-2 Exoribonuclease (NSP14) As a Potential Therapeutic Target to Treat COVID-19. 2020.
BibTeX Click to copy
@article{a2020a,
title = {SARS-CoV-2 Exoribonuclease (NSP14) As a Potential Therapeutic Target to Treat COVID-19},
year = {2020},
author = {Cruz-González, A. and Aguilar-Cámara, Abelardo and Alvarez-Carreño, Claudia and Becerra, A. and Campillo-Balderas, J. A. and Cisneros-Martínez, A. and Córdova-Villalba, Grisel and Cottom-Salas, W. and Cruz-González, Coral and Hernández-Morales, R. and Miranda-Pérez, Ingrid and Muñoz-Velasco, I. and Quintero-Navarro, Luis Alonso and Rivas, Mario and Cabañas, Noel and Sánchez-Rocha, Alma Carolina and Vázquez-Salazar, A. and Jácome, R. and Lazcano, A.}
}
Although the global health emergency caused by SARS-CoV-2 has led to unprecedented health and socioeconomic crisis, as of today neither an antiviral treatment has been approved for COVID-19, nor is a vaccine available. Like other coronaviruses, SARS-CoV-2 encodes a 3’-5’ exoribonuclease whose proofreading activity contributes to the maintenance of its large genome integrity and stability. The viral exonuclease shares biochemical and structural properties with cellular DnaQ-like exonucleases, suggesting that it was snatched by an ancestral coronavirus. Structural superpositions of the viral exonuclease with its cellular homologs exhibit a remarkable degree of conservation. Accordingly, inhibition mechanisms targeting the catalytic core may block both the cellular and viral exonucleases. Although the SARS-CoV-2 exonuclease has received little attention in the struggle against the COVID-19 pandemic, molecular docking assay suggests that inhibitors of cellular exonucleases may have antiviral activity. Hence, we argue that drug development and testing should consider SARS-CoV-2’s exonuclease as a therapeutic target.